Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01545531 · ClinicalTrials.gov registry record
Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance
A clinical trial, sponsored by University of Washington.
- Completed
- Registry status
- 54
- Enrollment target
NCT01545531: Completed study, sponsored by University of Washington.
NCT01545531 is a clinical trial that has completed, run by University of Washington. The registered enrollment target is 54 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01545531 has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to measure glomerular filtration rate (GFR) by iohexol plasma disappearance (gold standard) and measure serum Cystatin C levels (surrogate marker) in patients enrolled in our prospective study at baseline, day 100 and 1 year after hematopoietic cell transplant and determine if these levels correlate with serum creatinine and an estimated GFR using the Modification of Diet in Renal Disease (MDRD) equation and Schwartz formula in children.
Interventions
- DRUG Iohexol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2008-09 |
| Est. Completion | 2016-01 |
What the finished NCT01545531 record still lists
NCT01545531 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 54 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Iohexol is the first listed.
NCT01545531 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01545531 about?
NCT01545531 is a clinical study titled "Two-Point Measurement of Glomerular Filtration Rate by Iohexol Plasma Disappearance". The purpose of this study is to measure glomerular filtration rate (GFR) by iohexol plasma disappearance (gold standard) and measure serum Cystatin C levels (surrogate marker) in patients enrolled in our prospective study at baseline, day 100 and 1 year after hematopoietic cell transplant and determ...
What is the current status of trial NCT01545531?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2008-09. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01545531?
The interventions under investigation include: Iohexol (DRUG).
Who is sponsoring clinical trial NCT01545531?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia